OncoMatch/Clinical Trials/NCT06026878

GNT Induction Treatment in Locally Advanced NPC

Is NCT06026878 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including gemcitabine,nimotuzumab, toripalimab and gemcitabine, cisplatin for nasopharyngeal carcinoma.

Phase 3RecruitingAir Force Military Medical University, ChinaNCT06026878Data as of May 2026

Treatment: gemcitabine,nimotuzumab, toripalimab · gemcitabine, cisplatin — The goal of this clinical trial is to compare overall response rate between gemcitabine, nimotuzumab and toripalimab as induction treatment and gemcitabine combined with cisplatine in paitents with locally advanced nasopharyngeal carcinoma. It aims to answer whether gemcitabine, nimotuzumab and toripalimab as induction treatment show non-inferiority compared to GP induction chemotherapy. Participants will be randomly divided into two induction treatment groups.

Check if I qualify

Extracted eligibility criteria

Cancer type

Head and Neck Squamous Cell Carcinoma

Disease stage

Required: Stage III, IVB

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: immunotherapy

Patients who have previously undergone immunotherapy

Cannot have received: targeted therapy

Patients who have previously undergone...targeted therapy

Lab requirements

Blood counts

white blood cell count ≥4×10^9/L; absolute neutrophil count ≥1.5×10^9/L; platelets ≥100×10^9/L; hemoglobin ≥90 g/L

Kidney function

serum creatinine ≤1.5×ULN or creatinine clearance rate (CrCl) > 60 mL/min (Cockcroft-Gault formula)

Liver function

serum total bilirubin ≤1.5×ULN; AST ≤2.5×ULN; ALT ≤2.5×ULN

Basic hematological parameters are normal: white blood cell count ≥4×10^9/L; absolute neutrophil count ≥1.5×10^9/L; platelets ≥100×10^9/L; hemoglobin ≥90 g/L. Basically normal renal function: serum creatinine ≤1.5×ULN or creatinine clearance rate (CrCl) > 60 mL/min (using the Cockcroft-Gault formula)... Basically normal liver function: serum total bilirubin ≤1.5×ULN; aspartate aminotransferase (AST) ≤2.5×ULN; alanine aminotransferase (ALT) ≤2.5×ULN.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify